Granules India Limited
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, s… Read more
Granules India Limited (GRANULES) - Net Assets
Latest net assets as of September 2025: ₹39.83 Billion INR
Based on the latest financial reports, Granules India Limited (GRANULES) has net assets worth ₹39.83 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹69.44 Billion) and total liabilities (₹29.61 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹39.83 Billion |
| % of Total Assets | 57.36% |
| Annual Growth Rate | 22.42% |
| 5-Year Change | 70.97% |
| 10-Year Change | 457.86% |
| Growth Volatility | 24.13 |
Granules India Limited - Net Assets Trend (2006–2025)
This chart illustrates how Granules India Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Granules India Limited (2006–2025)
The table below shows the annual net assets of Granules India Limited from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹37.16 Billion | +15.19% |
| 2024-03-31 | ₹32.26 Billion | +13.78% |
| 2023-03-31 | ₹28.35 Billion | +9.58% |
| 2022-03-31 | ₹25.87 Billion | +19.04% |
| 2021-03-31 | ₹21.73 Billion | +17.87% |
| 2020-03-31 | ₹18.44 Billion | +20.55% |
| 2019-03-31 | ₹15.29 Billion | +17.28% |
| 2018-03-31 | ₹13.04 Billion | +44.33% |
| 2017-03-31 | ₹9.04 Billion | +35.67% |
| 2016-03-31 | ₹6.66 Billion | +54.47% |
| 2015-03-31 | ₹4.31 Billion | +21.13% |
| 2014-03-31 | ₹3.56 Billion | +29.51% |
| 2013-03-31 | ₹2.75 Billion | +12.14% |
| 2012-03-31 | ₹2.45 Billion | +11.52% |
| 2011-03-31 | ₹2.20 Billion | +8.60% |
| 2010-03-31 | ₹2.02 Billion | +15.68% |
| 2009-03-31 | ₹1.75 Billion | +0.76% |
| 2008-03-31 | ₹1.74 Billion | +3.71% |
| 2007-03-31 | ₹1.67 Billion | +110.48% |
| 2006-03-31 | ₹795.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Granules India Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3059482000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹30.59 Billion | 82.34% |
| Common Stock | ₹242.54 Million | 0.65% |
| Other Components | ₹6.32 Billion | 17.01% |
| Total Equity | ₹37.16 Billion | 100.00% |
Granules India Limited Competitors by Market Cap
The table below lists competitors of Granules India Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jafron Biomedical Co Ltd
SHE:300529
|
$965.46 Million |
|
Dime Community Bancshares, Inc. 9.000% Fixed-to-Floating Rate Subordinated Notes due 2034
NASDAQ:DCOMG
|
$965.68 Million |
|
Montnets Cloud Technology Group Co Ltd
SHE:002123
|
$965.78 Million |
|
Life Healthcare Group Holdings
PINK:LTGHY
|
$965.94 Million |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
$964.53 Million |
|
Grupo Bafar S.A.B. de C.V
MX:BAFARB
|
$964.26 Million |
|
BIRD CONSTRUCTION
F:6LT
|
$963.96 Million |
|
QUIDELORTHO DL-001
F:QL1A
|
$963.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Granules India Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 32,255,440,000 to 37,155,780,000, a change of 4,900,340,000 (15.2%).
- Net income of 5,015,160,000 contributed positively to equity growth.
- Dividend payments of 363,550,000 reduced retained earnings.
- Share repurchases of 49,980,000 reduced equity.
- New share issuances of 49,980,000 increased equity.
- Other comprehensive income decreased equity by 4,525,360,000.
- Other factors increased equity by 4,774,090,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹5.02 Billion | +13.5% |
| Dividends Paid | ₹363.55 Million | -0.98% |
| Share Repurchases | ₹49.98 Million | -0.13% |
| Share Issuances | ₹49.98 Million | +0.13% |
| Other Comprehensive Income | ₹-4.53 Billion | -12.18% |
| Other Changes | ₹4.77 Billion | +12.85% |
| Total Change | ₹- | 15.19% |
Book Value vs Market Value Analysis
This analysis compares Granules India Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 101.01x to 3.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | ₹5.81 | ₹586.75 | x |
| 2007-03-31 | ₹11.27 | ₹586.75 | x |
| 2008-03-31 | ₹8.02 | ₹586.75 | x |
| 2009-03-31 | ₹8.72 | ₹586.75 | x |
| 2010-03-31 | ₹10.05 | ₹586.75 | x |
| 2011-03-31 | ₹10.91 | ₹586.75 | x |
| 2012-03-31 | ₹12.17 | ₹586.75 | x |
| 2013-03-31 | ₹13.32 | ₹586.75 | x |
| 2014-03-31 | ₹17.27 | ₹586.75 | x |
| 2015-03-31 | ₹20.92 | ₹586.75 | x |
| 2016-03-31 | ₹31.58 | ₹586.75 | x |
| 2017-03-31 | ₹41.08 | ₹586.75 | x |
| 2018-03-31 | ₹53.83 | ₹586.75 | x |
| 2019-03-31 | ₹60.01 | ₹586.75 | x |
| 2020-03-31 | ₹72.28 | ₹586.75 | x |
| 2021-03-31 | ₹86.83 | ₹586.75 | x |
| 2022-03-31 | ₹104.04 | ₹586.75 | x |
| 2023-03-31 | ₹115.36 | ₹586.75 | x |
| 2024-03-31 | ₹133.09 | ₹586.75 | x |
| 2025-03-31 | ₹153.22 | ₹586.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Granules India Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.50%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.19%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 1.68x
- Recent ROE (13.50%) is below the historical average (14.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 9.26% | 4.12% | 0.81x | 2.78x | ₹-5.85 Million |
| 2007 | 4.54% | 4.04% | 0.57x | 1.97x | ₹-91.46 Million |
| 2008 | 5.19% | 3.51% | 0.69x | 2.14x | ₹-83.58 Million |
| 2009 | 4.95% | 3.00% | 0.71x | 2.31x | ₹-88.35 Million |
| 2010 | 15.01% | 6.59% | 1.12x | 2.04x | ₹101.34 Million |
| 2011 | 9.51% | 4.40% | 1.09x | 1.98x | ₹-10.82 Million |
| 2012 | 12.22% | 4.58% | 1.14x | 2.33x | ₹54.44 Million |
| 2013 | 11.85% | 4.26% | 1.12x | 2.48x | ₹50.82 Million |
| 2014 | 21.13% | 6.86% | 1.11x | 2.79x | ₹396.35 Million |
| 2015 | 21.08% | 7.03% | 1.08x | 2.78x | ₹477.91 Million |
| 2016 | 18.47% | 9.06% | 0.93x | 2.18x | ₹563.97 Million |
| 2017 | 18.21% | 11.66% | 0.75x | 2.08x | ₹741.60 Million |
| 2018 | 10.17% | 7.87% | 0.64x | 2.03x | ₹21.74 Million |
| 2019 | 15.46% | 10.37% | 0.76x | 1.95x | ₹834.61 Million |
| 2020 | 18.19% | 12.91% | 0.79x | 1.79x | ₹1.51 Billion |
| 2021 | 25.28% | 16.97% | 0.87x | 1.71x | ₹3.32 Billion |
| 2022 | 15.96% | 10.96% | 0.83x | 1.74x | ₹1.54 Billion |
| 2023 | 18.22% | 11.45% | 0.92x | 1.73x | ₹2.33 Billion |
| 2024 | 12.57% | 8.99% | 0.82x | 1.71x | ₹827.56 Million |
| 2025 | 13.50% | 11.19% | 0.72x | 1.68x | ₹1.30 Billion |
Industry Comparison
This section compares Granules India Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $17,182,683,300
- Average return on equity (ROE) among peers: 11.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Granules India Limited (GRANULES) | ₹39.83 Billion | 9.26% | 0.74x | $965.00 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $366.97 Million | 3.51% | 2.41x | $11.49 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.27 Million | -2.03% | 0.10x | $351.56 Million |
| Abbott India Limited (ABBOTINDIA) | $11.96 Billion | 21.35% | 0.35x | $1.60 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $37.90 Billion | 24.28% | 0.32x | $1.51 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.79 Million |
| Albert David Limited (ALBERTDAVD) | $1.86 Billion | 5.29% | 0.56x | $16.25 Million |
| Alivus Life Sciences Limited (ALIVUS) | $21.38 Billion | 21.84% | 0.26x | $329.34 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $1.71 Billion | 11.38% | 0.30x | $5.51 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $964.67 Million | 9.99% | 0.49x | $81.74 Million |